Clinical and molecular monitoring ofPlasmodium falciparumresistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012–2014
Authors:
- 19 May 2017
- journal article
- research article
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 111 (4) , 186-194
Abstract
The spread of P. falciparum resistant strain has led to a significant resurgence of malaria morbidity and mortality. The current cornerstone in malaria treatment in India is Artemisinin based Combination (Artesunate + Sulphadoxine-Pyrimethamine) Therapy (ACT) for treatment of uncomplicated P. falciparum malaria since 2010. In the present study we assessed the therapeutic efficacy of ACT and molecular monitoring of antimalarial resistance. Therapeutic efficacy was determined by in vivo method using 28 days follow-up. Molecular genotyping of dihydrofolate reductase (dhfr), dihydropteroate synthase (dhps) and kelch13 genes were analyzed. msp-1 and msp-2 genotyping were used to differentiate recrudescence. Therapeutic efficacy of ACT was determined in 237 patients over the three year period. Most of the patients showed adequate clinical and parasitological response (99.6%). Molecular study revealed that 72% parasites were of mutant genotype (27.2% single mutants, 43.5% double mutants and 1.3% triple mutants) for pfdhfr while pfdhps showed 78.2% wild type alleles and 21.8% mutants (18.1% single mutants and 3.7% double mutants). Analysis of total 135 samples revealed mutation in k13 gene along with non-synonymous single mutation at codon M579T (1.5%) and double mutations at codon M579T & N657H in 37%. ACT remains effective for the treatment of uncomplicated P. falciparum malaria in Madhya Pradesh, Central India. However, increasing mutation in pfdhfr (particularly triple mutations) and pfdhps may reduce susceptibility to partner drug SP and mutation in k13 propeller gene, highlighting the need for continuous monitoring of the efficacy of ACT.Keywords
Funding Information
- Indian Council of Medical Research (29/10/TransA/2010-ECD-II)
This publication has 41 references indexed in Scilit:
- A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern IndiaMalaria Journal, 2013
- Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern MyanmarPLOS ONE, 2013
- In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, VietnamMalaria Journal, 2012
- Comparative Efficacies of Artemisinin Combination Therapies in Plasmodium falciparum Malaria and Polymorphism of pfATPase6 , pfcrt , pfdhfr , and pfdhps Genes in Tea Gardens of Jalpaiguri District, IndiaAntimicrobial Agents and Chemotherapy, 2012
- Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal studyThe Lancet, 2012
- Evidence of Selective Sweeps in Genes Conferring Resistance to Chloroquine and Pyrimethamine in Plasmodium falciparum Isolates in IndiaAntimicrobial Agents and Chemotherapy, 2010
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Fighting malaria in Madhya Pradesh (Central India): Are we loosing the battle?Malaria Journal, 2009
- Similar Trends of Pyrimethamine Resistance-Associated Mutations in Plasmodium vivax and P. falciparumAntimicrobial Agents and Chemotherapy, 2007
- Prevalence of Mutations Associated with Higher Levels of Sulfadoxine-Pyrimethamine Resistance in Plasmodium falciparum Isolates from Car Nicobar Island and Assam, IndiaAntimicrobial Agents and Chemotherapy, 2006